Searched over 200M research papers
10 papers analyzed
Some studies suggest rosuvastatin may increase blood sugar by impairing beta cell function and increasing insulin resistance, while other studies indicate it can improve insulin sensitivity and inhibit atherogenesis.
6 papers analyzed
20 papers analyzed
Rosuvastatin, a widely used statin for lowering cholesterol, has been linked to changes in blood sugar levels. This article synthesizes findings from multiple studies to understand whether rosuvastatin raises blood sugar and its overall impact on glucose metabolism.
Research indicates that rosuvastatin can improve insulin sensitivity and increase glucose uptake in adipose tissue in mice on a normal diet. This suggests a potential benefit in glucose homeostasis under certain dietary conditions.
Conversely, other studies have shown that rosuvastatin can worsen insulin resistance. For instance, in hyperlipidemic patients with impaired fasting glucose, rosuvastatin treatment was associated with increased insulin resistance. Similarly, in HIV-infected adults on antiretroviral therapy, rosuvastatin significantly increased insulin resistance and fasting insulin levels.
Several studies have reported an increase in fasting blood sugar (FBS) levels with rosuvastatin use. In a comparative study with atorvastatin, rosuvastatin led to a significant rise in FBS levels in patients with type II diabetes mellitus. Additionally, in hypercholesterolemic patients, rosuvastatin dose-dependently increased insulin and glycated hemoglobin levels, indicating higher ambient glycemia.
The effects of rosuvastatin on glucose homeostasis appear to be complex and dose-dependent. While it can improve insulin sensitivity in some contexts, it also impairs beta-cell function and reduces insulin secretion, leading to higher blood glucose levels in other scenarios .
Rosuvastatin may modulate insulin signaling pathways, which can influence glucose metabolism. Studies in insulin-resistant mice have shown that rosuvastatin can partially reverse decreases in insulin receptor substrate 2 and protein kinase B pathways, improving insulin resistance independently of its cholesterol-lowering effects .
Rosuvastatin has been found to reduce adiponectin levels, a hormone that enhances insulin sensitivity. This reduction is associated with decreased insulin sensitivity and increased blood sugar levels in hypercholesterolemic patients.
In summary, while rosuvastatin can improve insulin sensitivity and glucose uptake in certain conditions, it also has the potential to increase fasting blood sugar levels and worsen insulin resistance, particularly in specific populations such as those with impaired fasting glucose or HIV. The dual effects of rosuvastatin on glucose homeostasis highlight the need for careful consideration of its use, especially in patients at risk of diabetes.
Most relevant research papers on this topic